kasofungin

Kasofungin is not a widely recognized antifungal drug in standard medical references. It may be a misspelling or alternate spelling of caspofungin, an echinocandin antifungal agent used to treat invasive Candida infections. If kasofungin denotes a different compound, reliable sources are not readily available.

Mechanism of action and class: Caspofungin inhibits β-(1,3)-D-glucan synthase, an enzyme essential for fungal cell wall synthesis. By disrupting cell wall formation, it weakens fungal cells and leads to their death. Echinocandins are fungicidal against most Candida species and are generally fungistatic against Aspergillus species; activity against other fungi is limited.

Spectrum and activity: Caspofungin is active against Candida species, including C. albicans and C. glabrata, with reduced activity against C. parapsilosis and limited activity against Cryptococcus species. Activity against Aspergillus species is variable, and caspofungin is not considered a first-line agent for aspergillosis in standard treatment guidelines.

Indications and usage: The main use is for invasive candidiasis, including candidemia, and for esophageal candidiasis. It is sometimes employed as salvage therapy for invasive aspergillosis in patients intolerant or refractory to other treatments, but it is not approved as a primary therapy for aspergillosis.

Administration and dosing: Caspofungin is administered intravenously. In adults, treatment regimens typically involve a loading dose followed by a daily maintenance dose, with exact dosing and duration determined by infection type and patient factors. Dosing adjustments may be specified for hepatic impairment; consult official labeling for specifics. It is not a pregnancy category drug without risk discussion.

Adverse effects and safety: Most adverse effects are mild but can include fever, rash, histamine-mediated infusion reactions, and elevated liver enzymes. Hepatic toxicity and hypersensitivity reactions are possible. Drug interactions can occur with concomitant therapies such as calcineurin inhibitors; liver function monitoring is advised during therapy.

Resistance and pharmacology: Resistance can arise from mutations in FKS1 or FKS2, which alter the glucan synthase target. Cross-resistance among echinocandins is possible but not universal.

History and regulatory status: Caspofungin was developed by Merck and approved by the U.S. FDA in the early 2000s for esophageal candidiasis and invasive candidiasis. It is marketed under the brand Cancidas in many regions and is part of the broader echinocandin class, which also includes micafungin and anidulafungin.